Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01016275
Other study ID # FMRP-007
Secondary ID
Status Completed
Phase N/A
First received November 18, 2009
Last updated August 5, 2014
Start date January 2010
Est. completion date October 2013

Study information

Verified date August 2014
Source Flanders Medical Research Program
Contact n/a
Is FDA regulated No
Health authority Belgium: Institutional Review Board
Study type Observational

Clinical Trial Summary

The objective of this clinical study is to evaluate, in a controlled setting, the long-term (up to 24 months) outcome of the self-expanding nitinol rapid-exchange Misago (Terumo) stent in TASC A and B iliac lesions.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date October 2013
Est. primary completion date October 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable for stenting (on indication for primary stenting, based on the discretion of the investigator)

- Patient presenting a score from 2 to 5 following Rutherford classification

- Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study

- Patient is >18 years old

- Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study

- Patient is eligible for treatment with the Misago (Terumo)

- The target lesion is either a modified TASC-II class A or B lesion with one of the listed specifications:

- Type A lesions

- Unilateral or bilateral stenoses of the Common Iliac Artery

- Unilateral or bilateral single short (=3 cm) stenosis of the External Iliac Artery

- Type B lesions

- Unilateral Common Iliac Artery occlusion

- Single or multiple stenosis totaling 3-10 cm involving the External Iliac Artery not extending into the Common Femoral Artery

- Unilateral External Iliac Artery occlusion not involving the origins of Internal Iliac Artery or Common Iliac Artery

- The target lesion has angiographic evidence of stenosis or restenosis > 50% or occlusion which can be passed with standard guidewire manipulation

- There is angiographic evidence of a patent Common an Deep Femoral Artery

Exclusion Criteria:

- The target lesion is either a modified TASC-II class B lesion with aortic lesion involvement:

- Short (=3 cm) stenosis of infrarenal aorta

- The target lesion is either a modified TASC-II class C or D lesion with aortic lesion involvement:

- Presence of aneurysm at the level of the iliac arteries

- Previously implanted stent(s) at the same lesion site

- Reference segment diameter is not suitable for available stent design

- Untreatable lesion located at the distal outflow arteries

- Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index procedure

- Patients refusing treatment

- Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated

- Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site

- Perforation at the angioplasty site evidenced by extravasation of contrast medium

- Patients with a history of prior life-threatening contrast medium reaction

- Patients with known hypersensitivity to nickel-titanium

- Patients with uncorrected bleeding disorders

- Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding

- Life expectancy of less than twelve months

- Any planned surgical intervention/procedure within 30 days of the study procedure

- Any patient considered to be hemodynamically unstable at onset of procedure

- Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Device:
Misago (stent placement)
Misago iliac stent

Locations

Country Name City State
Belgium Imelda Hospital Bonheiden Antwerp
Belgium AZ Sint-Blasius Dendermonde East-Flanders
Belgium UZ Gent Gent East-Flanders
Germany Herzzentrum Leipzig Leipzig Sachsen
Germany St Franziskus Hospital Münster Nordrhein-Westfalen

Sponsors (1)

Lead Sponsor Collaborator
Flanders Medical Research Program

Countries where clinical trial is conducted

Belgium,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary patency, defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without Target Lesion Revascularization (TLR) within 12 months. 12 months No
Secondary Technical success, defined as the ability to achieve final residual angiographic stenosis no greater than 30%. procedural No
Secondary Patients that present without a hemodynamically significant stenosis at the target area on duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without prior TLR are defined as being primary patent at the given follow-up. 1 & 24 months No
Secondary Clinical success, defined as an improvement of Rutherford classification of one class or more as compared to the pre-procedure Rutherford classification 1, 12 & 24 months No
Secondary Serious adverse events up to 24 months No
See also
  Status Clinical Trial Phase
Completed NCT01861860 - OPtimized Stenting Using Intravascular Ultrasound(IVUS) in Long lEsion: Rationale for Simplified criteriA N/A
Terminated NCT01305174 - Iliac, Common and External (ICE) Artery Stent Trial Phase 4
Recruiting NCT02468453 - VELOS for the Treatment of Vascular Lesions and Skin Rejuvenation N/A